专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2005049040A1 COMBINATIONS COMPRISING AMPA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF SCHIZOPHRENIA 审中-公开
标题翻译：包含AMPA受体拮抗剂用于治疗精神病药物的组合
公开(公告)号：WO2005049040A1
公开(公告)日：2005-06-02
申请号：PCT/EP2004/012150
申请日：2004-10-27
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , LINGENHÖHL, Kurt , MARTENYI, Ferenc , OFNER, Silvio , KAROLCHYK, Mary, Ann , O. KALKMAN, Hans
发明人： LINGENHÖHL, Kurt , MARTENYI, Ferenc , OFNER, Silvio , KAROLCHYK, Mary, Ann , O. KALKMAN, Hans
IPC分类号： A61K31/675
CPC分类号： A61K45/06 , A61K31/675 , A61K2300/00
摘要： The present invention relates to combinations suitable for the treatment of psychiatric/neurological disorders, in particular schizophrenia. The combinations comprise at least one AMPA receptor antagonist and at least one compound selected from the group consisting of (a) anti-epileptic drugs selected from barbiturates and derivatives thereof, benzodiazepines, carboxamides, hydantoins, succinimides, valproic acid and other fatty acid derivates and other anti-epileptic drugs, (b) conventional antipsychotics and (c) atypical antipsychotics.
摘要翻译：本发明涉及适用于治疗精神病/神经障碍，特别是精神分裂症的组合。所述组合包含至少一种AMPA受体拮抗剂和至少一种选自（a）选自巴比妥类及其衍生物，苯并二氮杂，甲酰胺，乙内酰脲，琥珀酰亚胺，丙戊酸和其它脂肪酸衍生物的抗癫痫药物的化合物和其他抗癫痫药，（b）常规抗精神病药和（c）非典型抗精神病药。

2. 发明申请

WO2005049039A1 COMBINATIONS COMPRISING AMPA RECEPTORS ANTAGONISTS FOR THE TREATMENT OF AFFECTIVE AND ATTENTION DEFICIT DISORDERS 审中-公开
标题翻译：包括AMPA受体拮抗剂在治疗感染和注意缺陷性疾病中的组合
公开(公告)号：WO2005049039A1
公开(公告)日：2005-06-02
申请号：PCT/EP2004/012145
申请日：2004-10-27
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , LINGENHÖHL, Kurt , MARTENYI, Ferenc , OFNER, Silvio , KAROLCHYK, Mary Ann , KALKMAN, Hans, O. , AITKEN, David
发明人： LINGENHÖHL, Kurt , MARTENYI, Ferenc , OFNER, Silvio , KAROLCHYK, Mary Ann , KALKMAN, Hans, O. , AITKEN, David
IPC分类号： A61K31/675
CPC分类号： A61K45/06 , A61K31/675 , A61K33/00 , A61K2300/00
摘要： The present invention relates to combinations suitable for the treatment of neurological/psychiatric disorders, in particular affective and attention disorders. The combination comprise at least one AMPA receptor antagonist and at least one compound selected from the group consisting of lithium, valproic acid sodium salt, conventional antipsychotics, atypical antipsychotics, lamotrigine, methylphenidate, antidepressants and antiepileptics.
摘要翻译：本发明涉及适用于治疗神经性/精神疾病，特别是情感和注意力障碍的组合。该组合包含至少一种AMPA受体拮抗剂和至少一种选自锂，丙戊酸钠盐，常规抗精神病药，非典型抗精神病药，拉莫三嗪，哌甲酯，抗抑郁药和抗癫痫药的化合物。

3. 发明申请

WO2005097138A3 COMBINATIONS COMPRISING OXCARBAZEPINE TO TREAT AFFECTIVE DISORDERS 审中-公开
标题翻译：包含奥沙利铂治疗有害疾病的组合
公开(公告)号：WO2005097138A3
公开(公告)日：2007-01-04
申请号：PCT/EP2005003385
申请日：2005-03-31
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , BOND JAMES , MARTENYI FERENC
发明人： BOND JAMES , MARTENYI FERENC
IPC分类号： A61K31/55 , A61K31/19 , A61K31/53 , A61K33/00 , A61K45/06 , A61P25/00
CPC分类号： A61K45/06 , A61K31/19 , A61K31/53 , A61K31/55 , A61K33/00 , A61K2300/00
摘要： The present invention relates to the treatment of affective disorders by administration of pharmaceutical oxcarbazepine combinations.
摘要翻译：本发明涉及通过给药奥卡西平组合治疗情感障碍。

4. 发明申请

WO2005094797A2 NOVEL USE OF AMPA-RECEPTOR ANTAGONISTS 审中-公开
标题翻译： AMPA受体拮抗剂的新用途
公开(公告)号：WO2005094797A2
公开(公告)日：2005-10-13
申请号：PCT/EP2005/002305
申请日：2005-03-04
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , LINGENHÖHL, Kurt , MARTENYI, Ferenc
发明人： LINGENHÖHL, Kurt , MARTENYI, Ferenc
IPC分类号： A61K31/00
CPC分类号： A61K31/00 , A61K31/675
摘要： The present invention relates to a method for the treatment and/or prevention dementia comprising the step of administering to a warm-blooded animal, including a human, in need thereof an effective amount of AMPA receptor antagonist alone or in combination with nootropics.
摘要翻译：本发明涉及治疗和/或预防痴呆的方法，其包括向有需要的温血动物（包括人）施用有效量的AMPA受体拮抗剂单独或与精神病药合用的步骤。

5. 发明申请

WO2004087168A1 USE OF 10-HYDROXY-10,11-DIHYDROCARBAMAZEPINE DERIVATIVES FOR THE TREATMENT OF AFFECTIVE DISORDERS 审中-公开
标题翻译：使用10-羟基-10,11-二氢氨基嘌呤衍生物治疗有害疾病
公开(公告)号：WO2004087168A1
公开(公告)日：2004-10-14
申请号：PCT/EP2004/003590
申请日：2004-04-01
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , MARTENYI, Ferenc , SCHMUTZ, Markus , ZECHNER, Stefanie
发明人： MARTENYI, Ferenc , SCHMUTZ, Markus , ZECHNER, Stefanie
IPC分类号： A61K31/55
CPC分类号： A61K31/55
摘要： The present invention relates to a method for the treatment, including the maintenance treatment, of affective disorders, which comprises administering, especially every 20 to 28 hours, to said subject a therapeutically effective amount, especially an amount between about 500 and about 3000 mg, of a compound of formula (I) wherein R 1 represents hydrogen or C 1 -C 3 alkyl carbonyl; to the use of a compound of (I) or a pharmaceutically acceptable salt thereof for the manufacture of a pharmaceutical composition for the treatment of affective disorders; to a combination comprising: (a) a compound of formula (I); and (b) at least one compound selected from the group consisting of lithium, divalproex, conventional antipsychotics, atypical antipsychotics, lamotrigine and antidepressants; and to the use of such combination for the treatment of affective disorders.
摘要翻译：本发明涉及一种用于治疗，包括维持治疗情感障碍的方法，其包括向所述受试者特别是每20至28小时施用治疗有效量，特别是约500至约3000mg的量，的式（I）化合物，其中R 1表示氢或C 1 -C 3烷基羰基; 涉及使用（I）化合物或其药学上可接受的盐在制备用于治疗情感障碍的药物组合物中的用途; 包括：（a）式（I）化合物; 和（b）至少一种选自锂，二戊二酸，常规抗精神病药，非典型抗精神病药，拉莫三嗪和抗抑郁药的化合物; 以及使用这种组合来治疗情感障碍。

6. 发明申请

WO2004087166A1 USE OF CARBAMAZEPINE DERIVATIVES FOR THE TREATMENT OF AGITATION IN DEMENTIA PATIENTS 审中-公开
标题翻译：卡巴胺衍生物用于治疗痴呆患者的呕吐的用途
公开(公告)号：WO2004087166A1
公开(公告)日：2004-10-14
申请号：PCT/EP2004/003418
申请日：2004-03-31
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , SHUA-HAIM, Joshua , MARTENYI, Ferenc
发明人： SHUA-HAIM, Joshua , MARTENYI, Ferenc
IPC分类号： A61K31/55
CPC分类号： A61K31/55
摘要： The present invention relates to the use of a compound of formula (I) wherein (a) R 1 and R 2 together form an oxy group or (b) R 1 is hydrogen and R 2 is hydroxy or acetoxy, or a pharmaceutically acceptable salt thereof, for the manufacture of a pharmaceutical composition for the treatment of agitation, in particular behavioral agitation, especially in dementia patients; a method for the treatment of agitation; pharmaceutical compositions comprising a compound of formula I; a combination comprising (a) a compound of formula I and (b) at least one compound selected from the group consisting of nootropic plant extracts, calcium antagonists, cholinesterase inhibitors, dihydroergotoxin, nicergoline, piracetame, purine derivates, pyritinol, vincamine and vinpocetine; and a commercial package including such combination.
摘要翻译：本发明涉及式（I）化合物的用途，其中（a）R 1和R 2一起形成氧基或（b）R 1是氢，R 2是羟基或乙酰氧基，或其药学上可接受的盐，用于制造用于治疗激动，特别是行为激动的药物组合物，特别是在痴呆患者中; 用于治疗激动的方法; 包含式I化合物的药物组合物; 一种组合，其包含（a）式I化合物和（b）选自由精调植物提取物，钙拮抗剂，胆碱酯酶抑制剂，二氢麦角毒素，麦角灵，piracetame，嘌呤衍生物，吡喹啉，长春胺和长春西汀的至少一种化合物; 以及包括这种组合的商业包装。

7. 发明申请

WO2005094797A3 USE OF AMPA-RECEPTOR ANTAGONISTS FOR TREATING DEMENTIA 审中-公开
标题翻译：使用AMPA受体拮抗剂治疗DEMENTIA
公开(公告)号：WO2005094797A3
公开(公告)日：2005-12-01
申请号：PCT/EP2005002305
申请日：2005-03-04
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , LINGENHOEHL KURT , MARTENYI FERENC
发明人： LINGENHOEHL KURT , MARTENYI FERENC
IPC分类号： A61K31/00 , A61K31/675 , A61K45/06 , A61P25/28
CPC分类号： A61K31/00 , A61K31/675
摘要： The present invention relates to a method for the treatment and/or prevention dementia comprising the step of administering to a warm-blooded animal, including a human, in need thereof an effective amount of AMPA receptor antagonist alone or in combination with nootropics.
摘要翻译：本发明涉及治疗和/或预防痴呆的方法，其包括向有需要的温血动物（包括人）施用有效量的AMPA受体拮抗剂单独或与精神病药合用的步骤。

8. 发明申请

WO2005097138A2 COMBINATIONS COMPRISING OXCARBAZEPINE TO TREAT AFFECTIVE DISORDERS 审中-公开
标题翻译：包含奥沙利铂治疗有害疾病的组合
公开(公告)号：WO2005097138A2
公开(公告)日：2005-10-20
申请号：PCT/EP2005/003385
申请日：2005-03-31
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , BOND, James , MARTENYI, Ferenc
发明人： BOND, James , MARTENYI, Ferenc
IPC分类号： A61K31/55
CPC分类号： A61K45/06 , A61K31/19 , A61K31/53 , A61K31/55 , A61K33/00 , A61K2300/00
摘要： The present invention relates to the treatment of affective disorders by administration of pharmaceutical oxcarbazepine combinations.
摘要翻译：本发明涉及通过给药奥卡西平组合治疗情感障碍。

9. 发明申请

WO2005049041A1 COMBINATIONS COMPRISING AMPA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ANXIETY DISORDERS 审中-公开
标题翻译：包含AMPA受体拮抗剂用于治疗无效疾病的组合
公开(公告)号：WO2005049041A1
公开(公告)日：2005-06-02
申请号：PCT/EP2004/012151
申请日：2004-10-27
申请人： NOVARTIS AG , NOVARTIS PHARMA GmbH , LINGENHÖHL, Kurt , MARTENYI, Ferenc , OFNER, Silvio , KAROLCHYK, Mary, Ann
发明人： LINGENHÖHL, Kurt , MARTENYI, Ferenc , OFNER, Silvio , KAROLCHYK, Mary, Ann
IPC分类号： A61K31/675
CPC分类号： A61K45/06 , A61K31/675 , A61K2300/00
摘要： The present invention relates to combinations suitable for the treatment of neurological psychiatric disorders, in particular anxiety disorders or other psychiatric disorders with underlying anxiety symptornatologies. The combinations comprise at least one AMPA receptor antagonist and at least one compound selected from the group consisting of benzodiazepines, selective serotonin reuptake inhibitors (SSRls), selective serotonin and norepinephrine reuptake inhibitors (SNRls), buspirone and pregabalin.
摘要翻译：本发明涉及适用于治疗神经精神障碍，特别是焦虑障碍或具有潜在焦虑症状的其他精神病症的组合。组合包含至少一种AMPA受体拮抗剂和至少一种选自苯并二氮杂，选择性5-羟色胺再摄取抑制剂（SSRls），选择性5-羟色胺和去甲肾上腺素再摄取抑制剂（SNRls），丁螺环酮和普瑞巴林的化合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式